Cargando…

Recent Advances and Disputes About Curcumin in Retinal Diseases

Curcumin belongs to the group of so-called phytocompounds, biologically active molecules produced by plants exerting a beneficial effect on health. Curcumin shows a wide spectrum of different properties, being an anti-inflammatory, antioxidant, antimicrobial and antimutagenic molecule. The purpose o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nebbioso, Marcella, Franzone, Federica, Greco, Antonio, Gharbiya, Magda, Bonfiglio, Vincenza, Polimeni, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219301/
https://www.ncbi.nlm.nih.gov/pubmed/34177257
http://dx.doi.org/10.2147/OPTH.S306706
_version_ 1783710897615667200
author Nebbioso, Marcella
Franzone, Federica
Greco, Antonio
Gharbiya, Magda
Bonfiglio, Vincenza
Polimeni, Antonella
author_facet Nebbioso, Marcella
Franzone, Federica
Greco, Antonio
Gharbiya, Magda
Bonfiglio, Vincenza
Polimeni, Antonella
author_sort Nebbioso, Marcella
collection PubMed
description Curcumin belongs to the group of so-called phytocompounds, biologically active molecules produced by plants exerting a beneficial effect on health. Curcumin shows a wide spectrum of different properties, being an anti-inflammatory, antioxidant, antimicrobial and antimutagenic molecule. The purpose of the review is to examine what literature reported on the characteristics of curcumin, particularly, on the beneficial and controversial aspects of this molecule, aiming for a better therapeutic management of retinal diseases. The retina is a constant target of oxidative stress, this tissue being characterized by cells rich in mitochondria and by vessels and being, obviously, continuously reached from photons affecting its layers. Particularly, the retinal ganglion cells and the photoreceptors are extremely sensitive to oxidative stress damage and it is well known that an imbalance in reactive oxygen species is often involved in several retinal diseases, such as uveitis, age-related macular degeneration, diabetic retinopathy, central serous chorioretinopathy, macular edema, retinal ischemia-reperfusion injury, proliferative vitreoretinopathy, hereditary tapeto-retinal degenerations, and retinal and choroidal tumors. To date, several studies suggest that oral treatment with curcumin is generally well tolerated in humans and, in addition, it seems to have no negative effects: therefore, curcumin is a promising candidate as a retinal disease therapy. Unfortunately, the primary limitation of curcumin is represented by its poor bioavailability, in fact only a minimal fraction of this substance can reach the blood stream in the form of a biologically active compound. However, many steps have been made in several fields. In the future, it is expected that the strategies developed until now to allow curcumin to reach the target tissues in adequate concentrations could be ameliorated and, above all, large in vivo studies on humans are needed to demonstrate the total safety of these compounds and their effectiveness in different eye diseases.
format Online
Article
Text
id pubmed-8219301
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82193012021-06-24 Recent Advances and Disputes About Curcumin in Retinal Diseases Nebbioso, Marcella Franzone, Federica Greco, Antonio Gharbiya, Magda Bonfiglio, Vincenza Polimeni, Antonella Clin Ophthalmol Review Curcumin belongs to the group of so-called phytocompounds, biologically active molecules produced by plants exerting a beneficial effect on health. Curcumin shows a wide spectrum of different properties, being an anti-inflammatory, antioxidant, antimicrobial and antimutagenic molecule. The purpose of the review is to examine what literature reported on the characteristics of curcumin, particularly, on the beneficial and controversial aspects of this molecule, aiming for a better therapeutic management of retinal diseases. The retina is a constant target of oxidative stress, this tissue being characterized by cells rich in mitochondria and by vessels and being, obviously, continuously reached from photons affecting its layers. Particularly, the retinal ganglion cells and the photoreceptors are extremely sensitive to oxidative stress damage and it is well known that an imbalance in reactive oxygen species is often involved in several retinal diseases, such as uveitis, age-related macular degeneration, diabetic retinopathy, central serous chorioretinopathy, macular edema, retinal ischemia-reperfusion injury, proliferative vitreoretinopathy, hereditary tapeto-retinal degenerations, and retinal and choroidal tumors. To date, several studies suggest that oral treatment with curcumin is generally well tolerated in humans and, in addition, it seems to have no negative effects: therefore, curcumin is a promising candidate as a retinal disease therapy. Unfortunately, the primary limitation of curcumin is represented by its poor bioavailability, in fact only a minimal fraction of this substance can reach the blood stream in the form of a biologically active compound. However, many steps have been made in several fields. In the future, it is expected that the strategies developed until now to allow curcumin to reach the target tissues in adequate concentrations could be ameliorated and, above all, large in vivo studies on humans are needed to demonstrate the total safety of these compounds and their effectiveness in different eye diseases. Dove 2021-06-18 /pmc/articles/PMC8219301/ /pubmed/34177257 http://dx.doi.org/10.2147/OPTH.S306706 Text en © 2021 Nebbioso et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Nebbioso, Marcella
Franzone, Federica
Greco, Antonio
Gharbiya, Magda
Bonfiglio, Vincenza
Polimeni, Antonella
Recent Advances and Disputes About Curcumin in Retinal Diseases
title Recent Advances and Disputes About Curcumin in Retinal Diseases
title_full Recent Advances and Disputes About Curcumin in Retinal Diseases
title_fullStr Recent Advances and Disputes About Curcumin in Retinal Diseases
title_full_unstemmed Recent Advances and Disputes About Curcumin in Retinal Diseases
title_short Recent Advances and Disputes About Curcumin in Retinal Diseases
title_sort recent advances and disputes about curcumin in retinal diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219301/
https://www.ncbi.nlm.nih.gov/pubmed/34177257
http://dx.doi.org/10.2147/OPTH.S306706
work_keys_str_mv AT nebbiosomarcella recentadvancesanddisputesaboutcurcumininretinaldiseases
AT franzonefederica recentadvancesanddisputesaboutcurcumininretinaldiseases
AT grecoantonio recentadvancesanddisputesaboutcurcumininretinaldiseases
AT gharbiyamagda recentadvancesanddisputesaboutcurcumininretinaldiseases
AT bonfigliovincenza recentadvancesanddisputesaboutcurcumininretinaldiseases
AT polimeniantonella recentadvancesanddisputesaboutcurcumininretinaldiseases